News for June 2016

News Archive

Owlstone Medical closes $7M (£4.9M) investment to commercialize disease breathalyzer Owlstone Medical closes $7M (£4.9M) investment to commercialize disease breathalyzer

Investment will fund ongoing clinical trials in lung and colon cancer screening

New TSRI Method Opens Door to Development of Many New Medicines New TSRI Method Opens Door to Development of Many New Medicines

Findings Reveal Human Proteins Are Better Drug Targets than Previously Thought

MRC Technology and AstraZeneca call for epigenetic targets in respiratory disease MRC Technology and AstraZeneca call for epigenetic targets in respiratory disease

MRC Technology (MRCT), a medical research charity, and AstraZeneca, a global biopharmaceutical company, are launching an initiative to find new epigenetic drug targets in respiratory disease. MRCT and AstraZeneca are now seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.

The Current issue of “The view from here” is concerned with Cancer. The Current issue of “The view from here” is concerned with Cancer.

The topic of this month’s newsletter from Drug Discovery Today is “Cancer”.

Attracting and Training the Next Generation of Medicinal Chemists Attracting and Training the Next Generation of Medicinal Chemists

By Steve Carney. Since I’ve been the Editor of Drug Discovery Today, I have made the conscious effort to include articles of interest to medicinal chemists in the Pharmaceutical and Biotech industries. Not least because Medicinal Chemists make up (still) a very significant proportion of the Pharma discovery community, but also because their efforts produce the lifeblood of the Pharma pipelines, although marginally less now with the advent and success of biological therapies.

Drug prices post-Brexit – an expensive pill to swallow? Drug prices post-Brexit – an expensive pill to swallow?

Much has already been written about the potential effects of Brexit on both the British economy as well as the rest of the word, vis-à-vis effects on immigration, employment, wages, inflation, investment, growth and so forth, and by now we know that either the sky is going to fall or it will be like manna falling from the sky. Definitely one of those two. Reality however is a bit more nuanced, and what follows may be sector specific and depend on the regulations and terms that are negotiated upon exit.

Welsh and Syrian scientists use date seeds to conquer toxins Welsh and Syrian scientists use date seeds to conquer toxins

Some of the most deadly environmental toxins, including dioxins, could soon be a thing of the past – thanks to the joint efforts of a Welsh scientist and partners in Syria and France.

Bubbly drinks inspire more effective cancer treatment Bubbly drinks inspire more effective cancer treatment

CANCER RESEARCH UK scientists are developing a bubbly drink packed with oxygen microbubbles to make treatments more potent for hard to treat tumours like pancreatic cancer.

TARANTULA venom is being used to help develop pain relief medications for people suffering from Irritable Bowel Syndrome. TARANTULA venom is being used to help develop pain relief medications for people suffering from Irritable Bowel Syndrome.

Researchers from The University of Adelaide in South Australia found that a specific peptide in the spider venom could be used to understand how people sense pain.

£15 billion and counting… Can we afford our medicine? £15 billion and counting… Can we afford our medicine?

Patient engagement is the key to unlocking the pressing issue of how the UK can afford its increasing expenditure on medicines – according to speakers at a public event held by the British Pharmacological Society on 9 June during The Times Cheltenham Science Festival. Entitled “Can we afford our medicine?”, the event will call for research to understand UK patients’ preferences: • Which areas of medicine should be prioritised nationally?• At what level or in what circumstances do improvements in life expectancy or quality of life represent value for money? • How would society benefit from improved use of anonymised patient medical records?

Genome engineering of quantifiable protein tags: Western blot on the way down? Genome engineering of quantifiable protein tags: Western blot on the way down?

Cell biologists’ most notorious approach to detect and semi-quantify proteins, western blotting, could well be on its way down. Professor Sven Eyckerman (VIB/UGent) and colleagues developed a set of universal protein tags that warrant protein quantification via targeted proteomics techniques. The development and applications of these new tags - named Proteotypic peptides for Quantification by SRM (PQS) - are described in the online, open access journal Scientific Reports.